Physician profile
Stephen Scharf
NPI 1629073671
$3,245.47
in general payments reported to CMS, 2019-2025
21 companies · $577 in 2025
The $577 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $220 · 2021: $272 · 2022: $909 · 2023: $482 · 2024: $394 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.52 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $478.58 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.34 | 2019-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $161.03 | 2021-2023 | |
| Daiichi Sankyo INC. | $137.98 | 2022-2023 | Injectafer |
| Neuraxis, INC. | $123.64 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $103.69 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $97.84 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $88.58 | 2024-2025 | Tremfya, Stelara, Simponi |
| Ipsen Biopharmaceuticals, INC | $78.73 | 2024-2025 | Iqirvo, Bylvay |
| Ucb, INC. | $61.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.91 | 2019-2023 | Dificid |
| Ardelyx, INC. | $44.56 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $41.90 | 2021-2023 | Suflave |
| Genzyme Corporation | $35.83 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $24.56 | 2025 | Ayvakit |
| Lilly USA, LLC | $20.73 | 2025 | Omvoh |
| Amgen INC. | $19.60 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.34 | 2025 | |
| Pfizer INC. | $12.80 | 2021 | |
| Mallinckrodt Hospital Products INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.